	US 12,280,106 B2
	Modified Marek's disease virus, and vaccines made therefrom
Joyce Pritchard, Gainesville, GA (US); Teshome Mebatsion, Watkinsville, GA (US); and Michel Bublot, Chaponost (FR)
Assigned to Boehringer Ingelheim Animal Health USA Inc., Duluth, GA (US)
Filed by Boehringer Ingelheim Animal Health USA Inc., Duluth, GA (US)
Filed on Nov. 23, 2022, as Appl. No. 18/058,619.
Application 18/058,619 is a continuation of application No. 16/262,774, filed on Jan. 30, 2019, granted, now 11,510,978.
Application 16/262,774 is a continuation of application No. 13/841,684, filed on Mar. 15, 2013, abandoned.
Claims priority of provisional application 61/614,142, filed on Mar. 22, 2012.
Prior Publication US 2023/0310589 A1, Oct. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/255 (2006.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/255 (2013.01) [A61K 39/12 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/552 (2013.01); C12N 2710/16334 (2013.01); C12N 2740/13022 (2013.01); C12N 2830/60 (2013.01)]

15 Claims

1. A method of eliciting a protective immune response against Marek's Disease virus (MDV) in an avian, comprising administering to the avian a therapeutically effective amount of a composition,

wherein the composition comprises a viral agent stably transformed with a foreign DNA construct comprising a long terminal repeat (LTR) sequence of a reticuloendotheliosis virus,

wherein the viral agent is a clonal virus, and not a mixed population of parental and recombinant virus, and

wherein the viral agent is a CVI988/X MDV SR-1 RN1250 deposited at ATCC under the accession number PTA-122066.